- Home
- SLP vs SLN Comparison
SLP vs SLN Comparison
Compare SLP & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- SLN
- Stock Information
- Founded
- SLP 1996
- SLN 1994
- Country
- SLP United States
- SLN United Kingdom
- Employees
- SLP N/A
- SLN N/A
- Industry
- SLP EDP Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- SLP Technology
- SLN Health Care
- Exchange
- SLP Nasdaq
- SLN Nasdaq
- Market Cap
- SLP 261.0M
- SLN 299.4M
- IPO Year
- SLP 1997
- SLN N/A
- Fundamental
- Price
- SLP $13.64
- SLN $5.92
- Analyst Decision
- SLP Buy
- SLN Buy
- Analyst Count
- SLP 7
- SLN 5
- Target Price
- SLP $29.50
- SLN $32.60
- AVG Volume (30 Days)
- SLP 1.0M
- SLN 84.9K
- Earning Date
- SLP 07-14-2025
- SLN 08-14-2025
- Dividend Yield
- SLP N/A
- SLN N/A
- EPS Growth
- SLP N/A
- SLN N/A
- EPS
- SLP N/A
- SLN N/A
- Revenue
- SLP $80,383,000.00
- SLN $27,701,000.00
- Revenue This Year
- SLP $19.69
- SLN N/A
- Revenue Next Year
- SLP $6.95
- SLN N/A
- P/E Ratio
- SLP N/A
- SLN N/A
- Revenue Growth
- SLP 20.01
- SLN N/A
- 52 Week Low
- SLP $12.39
- SLN $1.97
- 52 Week High
- SLP $42.11
- SLN $21.50
- Technical
- Relative Strength Index (RSI)
- SLP 31.12
- SLN 48.95
- Support Level
- SLP $12.97
- SLN $5.76
- Resistance Level
- SLP $13.55
- SLN $6.40
- Average True Range (ATR)
- SLP 0.77
- SLN 0.44
- MACD
- SLP 0.24
- SLN -0.06
- Stochastic Oscillator
- SLP 21.93
- SLN 18.03
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.